Louis-Solal Giboin, Cedric Simillion, Johannes Rennig, Atieh Bamdadian, Fiona C Kinsella, Anne V Smith, Peter McColgan, Michael Lindemann, Florian Lipsmeier, Edward J Wild, Jonas Dorn
{"title":"A digital motor score for sensitive detection of progression in Huntington’s disease","authors":"Louis-Solal Giboin, Cedric Simillion, Johannes Rennig, Atieh Bamdadian, Fiona C Kinsella, Anne V Smith, Peter McColgan, Michael Lindemann, Florian Lipsmeier, Edward J Wild, Jonas Dorn","doi":"10.1093/brain/awaf127","DOIUrl":null,"url":null,"abstract":"Remote digital monitoring of Huntington’s disease (HD) has potential to enhance the development of therapeutics, but no data-driven digital motor score exists to quantify the diversity of disease manifestations and track their progression. The Huntington’s Disease Digital Motor progression Score (HDDMS), co-designed by people with HD and neurologists, is a composite score for measuring motor progression of HD in clinical research. It is derived from smartphone sensor-based motor tests included in a remote HD digital monitoring platform. Developing the HDDMS involved selecting features that quantify test performance according to desired measurement properties and combining these features in a weighted composite score using factor analysis. It was developed and subsequently validated using data from four separate studies (HD Natural History Study [NCT03664804], open-label extension [OLE] of the tominersen Phase I/IIa study [NCT03342053], GENERATION HD1 [NCT03761849], and Digital-HD). Based on data from 1,008 individuals, the HDDMS encompasses balance, chorea, speeded tapping, and gait. It has favourable characteristics, including reliability (intraclass correlation coefficient > 0.95), correlation with the composite Unified Huntington’s Disease Rating Scale (cUHDRS) (r = −0.5), and better sensitivity to change (STC) than the cUHDRS. In a post-hoc analysis of GENERATION HD1, the STC of HDDMS at Week 20 was comparable to that of the cUHDRS at Week 68. The HDDMS promises substantial reduction in sample size in clinical trials.","PeriodicalId":9063,"journal":{"name":"Brain","volume":"117 1","pages":""},"PeriodicalIF":10.6000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/brain/awaf127","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Remote digital monitoring of Huntington’s disease (HD) has potential to enhance the development of therapeutics, but no data-driven digital motor score exists to quantify the diversity of disease manifestations and track their progression. The Huntington’s Disease Digital Motor progression Score (HDDMS), co-designed by people with HD and neurologists, is a composite score for measuring motor progression of HD in clinical research. It is derived from smartphone sensor-based motor tests included in a remote HD digital monitoring platform. Developing the HDDMS involved selecting features that quantify test performance according to desired measurement properties and combining these features in a weighted composite score using factor analysis. It was developed and subsequently validated using data from four separate studies (HD Natural History Study [NCT03664804], open-label extension [OLE] of the tominersen Phase I/IIa study [NCT03342053], GENERATION HD1 [NCT03761849], and Digital-HD). Based on data from 1,008 individuals, the HDDMS encompasses balance, chorea, speeded tapping, and gait. It has favourable characteristics, including reliability (intraclass correlation coefficient > 0.95), correlation with the composite Unified Huntington’s Disease Rating Scale (cUHDRS) (r = −0.5), and better sensitivity to change (STC) than the cUHDRS. In a post-hoc analysis of GENERATION HD1, the STC of HDDMS at Week 20 was comparable to that of the cUHDRS at Week 68. The HDDMS promises substantial reduction in sample size in clinical trials.
期刊介绍:
Brain, a journal focused on clinical neurology and translational neuroscience, has been publishing landmark papers since 1878. The journal aims to expand its scope by including studies that shed light on disease mechanisms and conducting innovative clinical trials for brain disorders. With a wide range of topics covered, the Editorial Board represents the international readership and diverse coverage of the journal. Accepted articles are promptly posted online, typically within a few weeks of acceptance. As of 2022, Brain holds an impressive impact factor of 14.5, according to the Journal Citation Reports.